

DOI: 10.7759/cureus.60059

Review began 04/21/2024 Review ended 05/07/2024 Published 05/10/2024

© Copyright 2024

K et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Low Anterior Resection Syndrome and Quality of Life of Patients After Sphincter Preservation Surgery: A Prospective Study

Chandramohan K 1, Akhil T. Jacob 1, Madhu Muralee 1, Mira W. Sudham 1, Mayadevi L 2, Sithara Balakrishnan 2

1. Surgical Oncology, Regional Cancer Centre, Trivandrum, IND 2. Nursing, Regional Cancer Centre, Trivandrum, IND

Corresponding author: Akhil T. Jacob, akhilthomasjacobrcc@gmail.com

Abstract

Background

After anterior resection (AR), one of the most debilitating complications is low anterior resection syndrome (LARS) seen in about 64% of patients. The severity of the LARS score was significantly correlated with neoadjuvant treatment, the extent of rectal surgery, complication by the anastomotic leak, female gender, and age < 64 years. In this study, we analyzed the impact of various clinical factors on LARS and also the various domains of quality of life (QoL).

Purpose

To assess the incidence of LARS in patients undergoing sphincter-sparing surgery for rectal cancer after the patient starts long-term defecating per anus, change in the QoL, and relation to LARS and factors affecting it

Methods

One year before, 72 patients who had undergone AR in the Regional Cancer Centre were interviewed by a trained interviewer and data was collected from the file. The questionnaires used were the Wexner Incontinence score, LARS Malayalam Questionnaire, and European Organisation For Research and Treatment of Cancer (EORTC) QLQ C30 Malayalam translations.

Statistical measures

The LARS score was used to categorize patients into three grades. The scores were compared with clinical and social factors using the $\chi 2$ test for association. Continuous variables were compared by the Spearman Rho test.

Results

Details of patients were studied (male: 55.6% (40) and female: 44.4% (32)). Fifty patients underwent low anterior resection (LAR). The mean LARS score was 25.61, with 47.2% of patients having severe LARS score. The mean Wexner score was 6.84. The relation with type of surgery, approach (laparoscopic vs open), or type of neoadjuvant therapy was not found to be significant. A higher LARS score did not impact overall QoL as assessed by FACT-C. Insomnia and diarrhea symptoms scores were significantly worsened. The pain score was worse for those undergoing stapler anastomosis. Wexner's score was worse for those who had received adjuvant chemotherapy. Role functioning score was better for AR compared to low anterior resection (LAR). Only distance from the anal verge was found to be a significant cause of LARS and was negatively correlated.

Discussion

LARS of severe degrees were seen in most patients. No modifiable risk factors were significantly found to affect the chance of LARS. However, LARS did not have a significant impact on QoL, neither did the type of surgery. So sphincter preservation can be offered to the patients, but all patients undergoing LAR should be counseled well about the risk of LARS before surgery.

 $\textbf{Categories:} \ \textbf{Gastroenterology, Oncology, Quality Improvement}$

Keywords: diarrhea, post-operative complications, constipation, stoma, rectal cancer, functional evaluation, quality of life, low anterior resection syndrome

Introduction

In the surgical management of rectal cancer, sphincter preservation is a much-desired outcome, provided oncological safety is not compromised. The surgical fraternity strives hard to perform low anterior



resection (LAR) even for very low rectal cancers. When the oncologic outcome is equivalent, preserving the sphincter is thought to result in a better quality of life (QoL). However, this enthusiasm is tempered by the reality that up to 70% of patients may develop bowel dysfunction, which may affect their QoL, post-stoma reversal [1-3]. The dysfunction of the defecatory and continence mechanism after LAR is called low anterior resection syndrome (LARS). The complex symptoms of LARS include multiple or frequent defecations, the sensation of incomplete bowel emptying, repetitive attempts with the passage of small quantities of fecal matter within a few hours (clustering), fecal incontinence (which may range from mild fecal soiling or incontinence of flatus to significant incontinence of liquid or solid fecal matter), urgency (the disability of inability to retain fecal matter more than 15 minutes after the onset of the sensation to defaecate). In the initial Danish studies, LARS was seen in 64% of subjects, the severity being minor in about 23% of the patients and major LARS in 41% of the patients. [4,5] The cause of LARS is multifactorial, which includes muscular and neural causes [6]. The different contributors include weak puborectalis muscle, internal sphincter injury, or indirect neural damage due to neuropraxia of branches of the autonomic nervous system in the course of resection of the lesion or due to radiotherapy (RT), absence of the recto-anal inhibitory signals, and decreased rectal compliance and capacity after excision [6-11]. The management of LARS depends on its severity and major manifestations. For minor LARS, symptom-related management is warranted, while for severe LARS management includes sacral nerve stimulation and pelvic floor rehabilitation. This study was presented as a poster at the NATCON 2022 and was published as a preprint on 27/7/2023 at Research Square.

Materials And Methods

This was a prospective observational study of patients from January 2021 to January 2023. Seventy-two patients who had undergone sphincter-sparing surgery in the Regional Cancer Centre, followed by stoma reversal, one year prior to the date of the interview were interviewed by the trained interviewer, and data was collected. The following questionnaires were used to study the severity of AR syndrome: Wexner Incontinence score is a tool filled in by the interviewer. The questionnaire was developed by Dr. Steven Wexner from Cleveland Clinic [5]. This questionnaire incorporates five qualifying symptoms, which include flatus incontinence, liquid incontinence, solid incontinence, requirement to wear incontinence pads, and requirement for lifestyle alteration. Scoring includes adding up the individual scores, with a range of zero to 20, with a zero score representing the status of no incontinence, and a score of more than nine is designated as a clinically significant incontinence score. LARS Malayalam Questionnaire: This is a patientadministered questionnaire. The tool was developed by Emmertsen et al. [4]. It consists of five qualifying characteristics flatus incontinence, liquid stool incontinence, frequency, clustering of defecation, and urgency. Each symptom category is given individual weightage, and a cumulative score is obtained with a range from zero to 42. The severity of defecatory dysfunction was classified as absence of LARS (score of zero to 20), minor degree LARS (score of 21-29), and major degree LARS (score of 30-42). EORTC QLQ C30 Malayalam Translations: EORTC QLQ C30 is a colorectal malignancy-specific, patient self-administered questionnaire designed to determine QoL for patients with or cured of malignancy. The questionnaire comprises 30 questions, and these are further utilized to come to a global health or QoL index, with five functional domains (which include physical, emotional, functional role, social functioning, and cognitive), three symptom domain scales (pain, fatigue, and nausea or vomiting) and six single-item domain questions (diarrhea, constipation, insomnia, loss of appetite, dyspnea, and financial impairment). Scoring of the QoL is done as prescribed by the scoring manual as formulated in the EORTC QLQ-C30 questionnaire. The symptom and function scores undergo linear transformation to scales of zero to 100 points. An increased functional score represents a higher functionality (optimal score being 100). Contrarily an elevated symptom score represents an increase in the severity of symptoms (the optimal score being zero). This study used the Malayalam version of the score.

The questionnaire was administered once, one year after ileostomy reversal. All data was collected after clearance of the Human Ethics Committee, and after obtaining written informed consent. The study was conducted in accordance with the principles enshrined in the Declaration of Helsinki. Various factors affecting AR syndrome were analyzed with EORTC QoL, Wexner score, and LARS score. The factors like age and gender; disease-related factors like location and stage; and treatment-related factors like type of surgery, type of anastomosis, and use of chemoradiation were analyzed against QoL, LARS, and Wexner scores. The LARS was used to categorize patients into three grades. Wexner, LARS, and QoL scores were compared with demographic factors, tumor characteristics, and treatment options using a $\chi 2$ test for association or the Kruskal-Wallis test for nonparametric variables and the Mann-Whitney U test when appropriate. P-values <0.05 were considered statistically significant. Unifactorial ordinal logistic regression was used to identify risk factors related to impairment of scores.

Results

Demographic details

The population comprised 40 males (55.6%) and 32 females (44.4%). Forty-three patients (59.7% of the population) were less than 60 years old. The mean age of the population is 56 with the range being from 28 to 75 years. Fifty-nine patients (92.2%) of the population had a good performance status of ECOG 0/1. The most common presenting complaint was bleeding per rectum, which was seen in 68 patients (83%), followed by constipation seen in 15 patients (20.8%). The mean distance from the analyerge was 7 cm with the



distance ranging from 2 cm to 15 cm from the anal verge. Of the 72 patients, 40 (57.1%) had undergone neoadjuvant chemoradiotherapy (NACTRT) and 15 (21.4%) had undergone short-course radiotherapy (SCRT), with 17 receiving no form of neoadjuvant treatment. Thirty-four (47.2%) of the cases were done via open approach and 29 (40.3%) laparoscopically. Two cases were started as laparoscopic approaches and later converted to open. Sixty-eight patients (93%) had stapled anastomosis. All had temporary diversion ileostomy except three patients. Fifty patients (69.4%) had undergone low anterior resection (LAR), one (1.4%) had undergone supra levator exenteration (SLE), and one (1.4%) had undergone total proctocolectomy (TPC).

Functional scores

The mean LARS score was 25.61. Fifty-four patients (75%) had some form of LARS with 34 patients (47.2%) having severe LARS scores. The mean Wexner score was 6.84. The Chi-square analysis of factors, including gender, age, procedure done, approach of surgery, use of RT, and whether a partial mesorectal excision (PME) or total mesorectal excision (TME) was done, have been correlated with LARS (Table 1).

| Parameter | | No LARS | Minor LARS | Major LARS | P-value |
|----------------|---------------------------|---------|------------|------------|---------|
| Gender | Male | 9 | 9 | 22 | 0.32 |
| | Female | 9 | 11 | 12 | 0.32 |
| | <40 | 3 | 4 | 2 | |
| | 41-50 | 2 | 3 | 8 | |
| Age | 51-60 | 5 | 6 | 10 | 0.226 |
| | 61-70 | 3 | 7 | 10 | |
| | >71 | 5 | 0 | 4 | |
| | LAR | 10 | 16 | 24 | |
| Procedure | AR | 7 | 4 | 9 | 0.417 |
| rioccaure | Supralevator exenteration | 1 | 0 | 0 | |
| | Total proctocolectomy | 0 | 0 | 1 | |
| Approach | Laparoscopic | 10 | 8 | 11 | 0.525 |
| , ipprodon | Open | 8 | 11 | 17 | |
| RT | Yes | 16 | 18 | 21 | 0.637 |
| 131 | No | 5 | 4 | 8 | 0.007 |
| TME vs PME | TME | 12 | 9 | 24 | 0.742 |
| TIVIL VS FIVIE | PME | 1 | 2 | 4 | 0.172 |

TABLE 1: Categorical factors associated with LARS score

 $TME, total\ mesorectal\ excision; AR, anterior\ resection; LARS, low\ anterior\ resection\ syndrome$

The relation of the type of surgery, approach (laparoscopic vs open), type of anastomosis (hand sewn vs stapled anastomosis), or type of neoadjuvant therapy were not found to be significantly related to LARS (Table 1).

When the correlation between LARS score and continuous variables was done, the time between neoadjuvant therapy to surgery, duration of temporary stoma, and age did not affect the scores. Rather only distance from the anal verge was found to be a significant cause of LARS. As the distance from the anal verge decreased, the chance of LARS increased (Table 2).



| Independent variables | Age | Distance from the anal verge | The time between neoadjuvant therapy to surgery | Duration of temporary stoma |
|-------------------------|-------|------------------------------|---|-----------------------------|
| Correlation coefficient | 0.063 | -0.284* | -0.183 | 0.193 |
| Sig. (two-tailed) | 0.600 | 0.016 | 0.186 | 0.149 |

TABLE 2: Correlation of LARS scores with continuous variables (Spearman Rho test)

*Significant correlation

Quality of life indices

Duration for which the temporary stoma was maintained correlated with a poorer emotional component of FACT-C, even at the later point of time, that is, one year after the stoma was reversed. Further patients with higher age had more impairment in the emotional component of FACT-C. The relation of the QoL domains was compared to categorical and continuous variables and is shown in Tables 3, 4.

| Parameter | | Total FACT-C ≤65.17 | Total FACT-C 65.18-83.50 | Total FACT-C >83.51+ | P-value | |
|-----------------------|---------------------------|---------------------|--------------------------|----------------------|---------|--|
| Gender | Male | 12 | 15 | 13 | 0.675 | |
| | Female | 12 | 9 | 11 | | |
| | LAR | 18 | 16 | 16 | | |
| Procedure | AR | 4 | 8 | 8 | 0.453 | |
| riocedure | Supralevator exenteration | 1 | 0 | 0 | 0.453 | |
| | TPC | 1 | 0 | 0 | | |
| Approach | Laparoscopic | 12 | 7 | 10 | 0.625 | |
| дри одон | Open | 11 | 14 | 11 | 0.025 | |
| | No | 4 | 0 | 3 | | |
| Neoadjuvant treatment | CTRT | 11 | 20 | 9 | 0.011 | |
| | SCRT | 5 | 0 | 4 | | |
| TME vs PME | TME | 19 | 16 | 10 | 0.148 | |
| TIME TO TIME | PME | 4 | 0 | 3 | 3.140 | |
| Temporary stoma | No | 2 | 1 | 3 | 0.294 | |
| remporary stoma | Yes | 22 | 21 | 63 | 0.234 | |

TABLE 3: Factors affecting quality of life (FACT-C)

AR, anterior resection; TPC, total proctocolectomy; CTRT, chemoradiotherapy; SCRT, short-course radiotherapy; TME, total mesorectal excision; PME, partial mesorectal excision; QoL, quality of life; LAR, low anterior resection

| Independent variables | Correlation coefficient | P-value |
|---|--|--|
| Age | 0.163 | 0.171 |
| Distance from anal verge | -0.034 | 0.779 |
| Time between neoadjuvant therapy to surgery | -0.090 | 0.517 |
| Duration of temporary stoma | -0.066 | 0.625 |
| | Age Distance from anal verge Time between neoadjuvant therapy to surgery | Age 0.163 Distance from anal verge -0.034 Time between neoadjuvant therapy to surgery -0.090 |



| | LARS | 0.104 | 0.675 |
|---|---|-----------------------------------|----------------------------------|
| | Age | .327** | 0.005 |
| | Distance from anal verge | -0.093 | 0.437 |
| Emotional well-being | Time between neoadjuvant therapy to surgery | 0.122 | 0.380 |
| | Duration of temporary stoma | .356** | 0.007 |
| | LARS | 0.099 | 0.467 |
| | Age | 0.081 | 0.501 |
| | Distance from anal verge | 0.044 | 0.717 |
| Functional well-being | Time between neoadjuvant therapy to surgery | 0.170 | 0.220 |
| | Duration of temporary stoma | 0.220 | 0.101 |
| | LARS | 0.017 | 0.171 |
| | Age | -0.041 | 0.730 |
| | Distance from anal verge | -0.129 | 0.280 |
| Additional concerns | Time between neoadjuvant therapy to surgery | -0.036 | 0.797 |
| | Duration of temporary stoma | 0.247 | 0.065 |
| | LARS | -0.049 | 0.156 |
| | Age | 0.161 | 0.177 |
| | Distance from anal verge | -0.023 | 0.849 |
| FACT-C total score | Time between neoadjuvant therapy to surgery | 0.092 | 0.510 |
| | Duration of temporary stoma | 0.237 | 0.076 |
| | LARS | 0.023 | 0.172 |
| | Age | -0.137 | 0.251 |
| | Distance from anal verge | -0.095 | 0.427 |
| Physical functionality | Time between neoadjuvant therapy to surgery | 0.025 | 0.858 |
| | Duration of temporary stoma | -0.131 | 0.331 |
| | LARS | -0.050 | 0.197 |
| | Age | 0.025 | 0.835 |
| | Distance from anal verge | 0.087 | 0.469 |
| Role functioning cumulative score | Time between neoadjuvant therapy to surgery | -0.029 | 0.834 |
| | Duration of temporary stoma | -0.065 | 0.630 |
| | LARS | -0.016 | 0.182 |
| | Age | 0.114 | 0.340 |
| | Distance from anal verge | -0.029 | 0.044 |
| | Distance nom and voige | 0.020 | 0.811 |
| Symptom scale: nausea and vomiting | Time between neoadjuvant therapy to surgery | -0.209 | 0.811 |
| Symptom scale: nausea and vomiting | | | |
| Symptom scale: nausea and vomiting | Time between neoadjuvant therapy to surgery | -0.209 | 0.129 |
| Symptom scale: nausea and vomiting | Time between neoadjuvant therapy to surgery Duration of temporary stoma | -0.209 0.114 | 0.129 |
| Symptom scale: nausea and vomiting | Time between neoadjuvant therapy to surgery Duration of temporary stoma LARS | -0.209 0.114 0.018 | 0.129 0.399 0.186 |
| Symptom scale: nausea and vomiting Emotional score | Time between neoadjuvant therapy to surgery Duration of temporary stoma LARS Age | -0.209 0.114 0.018 .250* | 0.129 0.399 0.186 0.034 |



| | LARS | -0.160 | 0.187 |
|------------------------------|---|--------|-------|
| | Age | 0.029 | 0.812 |
| | Distance from anal verge | 0.121 | 0.311 |
| Cognitive functioning score | Time between neoadjuvant therapy to surgery | 0.263 | 0.054 |
| | Duration of temporary stoma | -0.037 | 0.786 |
| | LARS | -0.116 | 0.563 |
| | Age | -0.027 | 0.823 |
| | Distance from anal verge | -0.031 | 0.799 |
| Social functioning score | Time between neoadjuvant therapy to surgery | 0.224 | 0.103 |
| | Duration of temporary stoma | -0.239 | 0.073 |
| | LARS | -0.169 | 0.112 |
| | Age | 0.033 | 0.785 |
| | Distance from anal verge | 0.125 | 0.297 |
| Global QoL score | Time between neoadjuvant therapy to surgery | .346* | 0.010 |
| | Duration of temporary stoma | 0.035 | 0.797 |
| | LARS | 0.138 | 0.221 |
| | Age | -0.025 | 0.834 |
| | Distance from anal verge | 0.130 | 0.277 |
| Dyspnea score | Time between neoadjuvant therapy to surgery | -0.111 | 0.426 |
| , , | Duration of temporary stoma | -0.216 | 0.106 |
| | LARS | -0.275 | 0.223 |
| | Age | -0.112 | 0.350 |
| | Distance from anal verge | -0.147 | 0.218 |
| Insomnia score | Time between neoadjuvant therapy to surgery | -0.234 | 0.089 |
| | Duration of temporary stoma | 0.176 | 0.192 |
| | LARS | 0.240 | 0.042 |
| | Age | -0.185 | 0.119 |
| | Distance from anal verge | 0.082 | 0.493 |
| Loss of appetite score | Time between neoadjuvant therapy to surgery | -0.193 | 0.161 |
| 2000 of appealed score | Duration of temporary stoma | -0.128 | 0.344 |
| | LARS | 0.085 | 0.112 |
| | Age | -0.116 | 0.331 |
| | Distance from anal verge | -0.011 | 0.929 |
| Nausea and vomiting score | Time between neoadjuvant therapy to surgery | -0.098 | 0.929 |
| Tradoca and vorniting source | Duration of temporary stoma | -0.234 | 0.481 |
| | LARS | 0.018 | 0.080 |
| | | -0.006 | 0.221 |
| | Age | -0.075 | 0.529 |
| Constinution seems | Distance from anal verge | | |
| Constipation score | Time between neoadjuvant therapy to surgery | -0.017 | 0.904 |



| | Duration of temporary stoma LARS | 0.077 -0.096 | 0.568 0.211 |
|----------------------------|---|-----------------|----------------|
| Diarrhea score | Age | -0.076 | 0.525 |
| | Distance from anal verge | -0.128 | 0.283 |
| | Time between neoadjuvant therapy to surgery | 0.012 | 0.933 |
| | Duration of temporary stoma | -0.111 | 0.412 |
| | LARS | 0.254 | 0.031 |
| | Age | -0.066 | 0.583 |
| | Distance from anal verge | 0.015 | 0.901 |
| Pain score | Time between neoadjuvant therapy to surgery | -0.192 | 0.163 |
| | Duration of temporary stoma | 0.076 | 0.576 |
| | LARS | 0.044 | 0.112 |
| Financial difficulty score | Age | 0.044 | 0.713 |
| | Distance from anal verge | 0.059 | 0.626 |
| | Time between neoadjuvant therapy to surgery | -0.179 | 0.195 |
| | Duration of temporary stoma | 0.165 | 0.219 |
| | LARS | 0.138 | 0.986 |

TABLE 4: Correlation of FACT QoL score with continuous variables (Spearman Rho test)

LARS, low anterior resection syndrome; QoL, quality of life

Patients who had undergone some forms of neoadjuvant therapy were found to have a worse QoL score. However, other modifiable factors were less likely to impact overall QoL.

A higher LARS score did not impact overall QoL as assessed by FACT-C as well as the global QoL as determined by the EORTC C30 score. However, the patients performed poorer in the diarrhea and insomnia symptom domains. With worse LARS scores, patients had a trend toward worse functional outcomes; however, this was not found to be statistically significant. None of the patients had received any treatment directed at LARS.

Discussion

In our population, the prevalence of LARS was 75% (54). Major LARS was seen in 47.2% (34) of the patients, which is similar to that found in most of the published data [4,8,12]. A study done in Italy reported long results indicating the prevalence and severity of the LARS score at a point more than 10 years after resection (93 participants were included with the median follow-up being 13.7 years) [13]. The study by Chen et al, done in 242 patients, with a median follow-up of 14.6 years showed that the LARS prevalence was 68%, which was of minor degree in 22% and of major severity in 46% [13]. No modifiable risk factors were significantly found to affect the chance of LARS. The only factor that was found to have a statistically significant relation to LARS was the distance from the anal verge. This may be due to the need for more dissection and difficulties encountered during low resection. However, the type of surgery was found not to be statistically significant in its relationship with LARS. This may be an indicator that the damage to surrounding structures and surgical difficulty may be more important than the level of anastomosis. According to the data from the Danish study group, the degree of LARS had a significant correlation with neoadjuvant therapy (with relative risk (RR) of 2.48), the extent of rectal surgery TME vs PME (with RR of 2.31), complication in the form of anastomotic leakage (RR being 2.06), younger chronological age (age less than 64 years old) (RR: 1.90), and female gender (RR: 1.35) [14,15]. The severity of the LARS score was maximum if the patient had undergone NACTRT + TME, compared to PME or TME alone. It usually takes approximately one year after surgery for the symptoms to plateau after which there will not be significant improvement. From the same data, Wiltink et al. noted that RT had a statistically significant impact on LARS when they compared the outcomes of the 241 patients who had undergone RT and those who did not do so (237 patients) with the median follow-up being 14 years [12].

^{**}Significant correlation coefficient



The reassuring aspect that has been determined in this study is that LARS did not have a significant impact on QoL. However, in comparison to the data from the same institution, the mean QoL score as determined by FACT-C was better for patients post-APR (74.35) when compared to patients with LARS (69.5). This may be due to the social limitations, wherein the public lavatory facilities may not be available readily, and the manual nature of the occupation of patients significantly impairing the functionality of the patients with LARS. Furthermore, on assessment of the symptom domains, patients with LARS had worse diarrhea scores and worse insomnia scores. The incomplete evacuation has resulted in increased frequency, which is perceived as diarrhea, and it is significant enough to affect sleep. Thus, patients were significantly affected by the LARS, with respect to bowel function and sleep; however, the effect of this may have been neutralized by the lack of significant difference in the social well-being and emotional score, which may be due to a permeating desire to avoid stoma, better family support, social accommodation, and robust stoma care and functional counseling provided, which prepares the patients to better tolerate the compromises of the LARS, thus protecting the overall QoL. So, sphincter preservation can be offered to the patients, explaining the possibility of developing LARS with proper counseling of the patient and their family members, so as to tide over the functional impairment.

The elderly population and those who have temporary stomas retained for longer periods of time are more likely to have worse emotional scores, as assessed by FACT-C. Prolonged retention of stoma, especially with the fluid nature of the ileal effluent, may significantly hamper the emotional status of the patients, which leaves behind a trauma that has a lasting impact on the patient's emotional well-being even as late as one year. This may act as an incentive toward considering early stoma reversal as much as feasible so as to improve the QoL and spare the patients from lasting emotional trauma. The elderly population is prone to emotional lability and depression due to age, comorbid issues, and sociocultural deficiencies. So the LARS can act as an additional stressor, which hampers the emotional QoL for this population. This is a small study involving 72 patients and hence there are limitations to the extent to which conclusions can be drawn from this. Furthermore, the assessment reported herein is at a single point in time so the dynamic changes have not been measured in this report, the assessment of which is still underway. In previous studies, it has been seen that the QoL outcomes reach a nadir by six months and then gradually improves [16].

Conclusions

In a society that very much desires a stoma-free life, sphincter-preserving procedures if oncologically safe can be offered. However, the patients have to be educated that their symptomatology may be significantly disturbing, and they may have a better QoL with a permanent stoma. The patients should be counseled appropriately, regarding what to expect and the family should be able to support the patient. The societal mechanisms should evolve to better help and support these individuals by providing sanitary facilities and public lavatories. This study is limited by the small sample size and further studies into this matter would be required to further elucidate the details and real-world impact of LARS.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Akhil T. Jacob, Chandramohan K, Madhu Muralee, Mira W. Sudham, Mayadevi L, Sithara Balakrishnan

Acquisition, analysis, or interpretation of data: Akhil T. Jacob, Chandramohan K, Madhu Muralee, Mira W. Sudham, Mayadevi L, Sithara Balakrishnan

Drafting of the manuscript: Akhil T. Jacob, Chandramohan K, Madhu Muralee, Mira W. Sudham, Mayadevi L. Sithara Balakrishnan

Critical review of the manuscript for important intellectual content: Akhil T. Jacob, Chandramohan K, Madhu Muralee, Mira W. Sudham, Mayadevi L, Sithara Balakrishnan

Supervision: Akhil T. Jacob, Chandramohan K, Madhu Muralee, Mira W. Sudham, Mayadevi L, Sithara Balakrishnan

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Human Ethics Committee of Regional Cancer Centre issued approval HEC No. 28/18. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or



within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

Dr. Immanuel Thomas, Former Professor and Head of Department of Psychology, Kerala University College helped in the analysis of the data. The data will be available at request to the corresponding author at akhilthomasjacobrcc@gmail.com

References

- Emmertsen KJ, Laurberg S: Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013, 100:1377-87. 10.1002/bjs.9223
- Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL.: Anterior resection syndrome. Lancet Oncol. 2012, 1016:1470-2045. 10.1016/S1470-2045(12)70236-X
- Juul T, Ahlberg M, Biondo S, et al.: Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum. 2014, 57:585-91. 10.1097/DCR.000000000000116
- Emmertsen KJ, Laurberg S: Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012, 255:922-8. 10.1097/SLA.0b013e31824f1c21
- Jorge JM, Wexner SD: Etiology and management of fecal incontinence. Dis Colon Rectum. 1993, 36:77-97. 10.1007/BF02050307
- Moszkowicz D, Peschaud F, Bessede T, Benoit G, Alsaid B: Internal anal sphincter parasympathetic-nitrergic and sympathetic-adrenergic innervation: a 3-dimensional morphological and functional analysis. Dis Colon Rectum. 2012, 55:473-81. 10.1097/DCR.0b013e318245190e
- How P, Evans J, Moran B, Swift I, Brown G: Preoperative MRI sphincter morphology and anal manometry: can they be markers of functional outcome following anterior resection for rectal cancer?. Colorectal Dis. 2012, 14:e339-45. 10.1111/j.1463-1318.2012.02942.x
- Ziv Y, Zbar A, Bar-Shavit Y, Igov I: Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations. Tech Coloproctol. 2013, 17:151-62. 10.1007/s10151-012-0909-3
- Bregendahl S, Emmertsen KJ, Fassov J, Krogh K, Zhao J, Gregersen H, Laurberg S: Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol. 2013, 108:331-6. 10.1016/j.radonc.2013.07.004
- Bakx R, Doeksen A, Slors JF, Bemelman WA, van Lanschot JJ, Boeckxstaens GE: Neorectal irritability after short-term preoperative radiotherapy and surgical resection for rectal cancer. Am J Gastroenterol. 2009, 104:133-41. 10.1038/aig.2008.2
- Mochiki E, Nakabayashi T, Suzuki H, Haga N, Fujita K, Asao T, Kuwano H: Barostat examination of proximal site of the anastomosis in patients with rectal cancer after low anterior resection. World J Surg. 2001, 25:1377-82. 10.1007/s00268-001-0144-y
- Wiltink LM, Chen TY, Nout RA, et al.: Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014, 50:2390-8. 10.1016/j.ejca.2014.06.020
- Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA, van de Velde CJ: Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015, 14:106-14. 10.1016/j.clcc.2014.12.007
- Bregendahl S, Emmertsen KJ, Lous J, Laurberg S: Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis. 2013. 15:1130-9. 10.1111/codi.12244
- Sturiale A, Martellucci J, Zurli L, et al.: Long-term functional follow-up after anterior rectal resection for cancer. Int J Colorectal Dis. 2017, 32:83-8. 10.1007/s00384-016-2659-6
- Yoo HJ, Kim JC, Eremenco S, Han OS: Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), Version 4. J Pain Symptom Manage. 2005, 30:24-32. 10.1016/j.jpainsymman.2004.12.009